A Phase 1, First-in-Human, clinical trial to evaluate the safety of Small Mobile Stem Cells (SMS) delivered into the lung as a potential Organ Regeneration Therapy in Chronic Obstructive Pulmonary Disease (SORT-COPD Study)

SMSbiotech Australia Pty Ltd0 个研究点目标入组 18 人开始时间: 2024年9月20日最近更新: 2024年9月30日

适应症

试验速览

阶段: Unknown
状态: 尚未招募
发起方
入组人数: 18

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Non-randomised trial
主要目的: Treatment
盲法: Open (masking not used)

入排标准

年龄范围: 39 Years 至 69 Years（—）
性别: All

入选标准

•Aged 39 to 69 years (inclusive).
•Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of nonchildbearing potential (WONCBP) OR Is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method from screening until 30 days after the last dose of study intervention. A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) at Screening and on Day 1, prior to administration of study intervention. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
•Male participants: Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 30 days after the last dose of study intervention: Refrain from donating fresh unwashed semen. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR must agree to use contraception/barrier (male condom).
•Has a diagnosis of mild or moderate COPD-C (cigarette smoking COPD) or COPD-P (biomass and pollution exposure COPD) according to the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Criteria. Lung impairment will be determined with post-bronchodilator FEV1 spirometry.
•Has previously received treatment for COPD-C or COPD-P.
•Has stable COPD disease state, defined as no exacerbations in the 12 weeks prior to screening, no hospitalizations in the 12 weeks prior to screening, and no changes in COPD medication in the 28 days prior to screening.
•Agrees to comply with study specific procedures and visits, including non-smoking during the treatment and follow-up periods of the study.
•Willing and able to provide written informed consent.

排除标准

•Previous or current diagnosis of COPD-G, COPD-D, COPD-I, COPD-A or COPD-U; asthma, congestive heart failure, bronchiectasis, tuberculosis, obliterative bronchiolitis or diffuse panbronchiolitis.
•Previous or current history of respiratory failure other than due to COPD (e.g. restrictive lung disease, sarcoidosis, tuberculosis, idiopathic pulmonary fibrosis, bronchiectasis, CMV pneumonitis, cystic fibrosis, asbestosis, silicosis or farmer’s lung disease), or detection of any of these conditions through screening CT scanning.
•History of COVID associated pneumonia with hypoxemic respiratory failure in the 12 weeks prior to screening.
•Current use, or use within 21 days of screening, of systemic corticosteroids. If currently prescribed Inhaled Corticosteroids, must be willing and able to avoid intake of the morning dose on the days of IP administration, and limit taking the dose until late evening (>12 hours after administration of IP.
•Any history of chronic liver disease, or abnormal liver function at screening, defined as: Alanine transaminase (ALT) and/or aspartate aminotransferase (AST) more than 2.5 times the upper limit of normal (ULN) Total bilirubin more than two times the ULN Participants with documented Gilbert’s syndrome are permitted to enter the study.
•History of renal insufficiency, defined as chronic kidney disease stage 2 to stage 5 as per KDIGO 2020 definitions.
•Uncontrolled hypertension, or current hypertension controlled on more than two medications.
•History of coronary artery disease, coronary artery bypass graft surgery, percutaneous transluminal coronary angioplasty, severe peripheral arterial disease, cerebrovascular disease (including history of transient ischemic attack or cerebrovascular accident).
•Type 1 or Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c > 7.5%) at screening.
•No active malignancy in the last three years, including any potential neoplasm detected via high-resolution CT scan (nodule > 5 mm) detected as part of the screening process. People with a history of basal cell or squamous cell carcinoma of the skin are eligible.
•History of HIV or other immunosuppressed conditions, Hepatitis B or Hepatitis C, or use of immunosuppressive medications within 14 days prior to screening, and for 3 weeks after the last dose of study intervention is administered.
•Active infection requiring systemic antibiotic treatment within 12 weeks prior to screening.
•Body mass index (BMI) > 60 kg/m
•Active smoking of tobacco or cannabis in the 28 days prior to screening, any use of nicotine containing products (vaping, nicotine patches, oral nicotine products or nicotine chewing gum), or as indicated by results of cotinine saliva testing, performed at screening.
•History of alcohol or other substance abuse.
•Pregnant or breastfeeding.
•Any severe medication allergy, including an allergy to bovine products.
•Any other medical condition, psychiatric condition or illness, that according to the Principal Investigator might render the subject unlikely to tolerate the inhalation of SORT-COPD (SMS cells), or to complete the study.
•Current participation in any other clinical trial or participation in the last six weeks or subject received an experimental therapy (drug or biologic) for any indication within 12 months prior to enrolment.
•Unable or unwilling to comply with study

研究者

发起方

SMSbiotech Australia Pty Ltd

相似试验

招募中

1 期

[M23-477] Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Acute myeloid leukemia

JPRN-jRCT2021230042Okubo Sumiko60

招募中

1 期

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) targeting PRAME, in Patients with Recurrent and/or Refractory Solid TumorsSolid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104

CTIS2022-503133-54-00Immatics Biotechnologies GmbH155

招募中

1 期

[M23-385]A Phase 1 study of ABBV-706 alone or in combination in adult subjects with advanced solid tumors.Advanced solid tumors with potential SEZ6 expression

JPRN-jRCT2031230510Yamagishi Chika350

已完成

1 期

First in human clinical study of a novel drug JNT-517 to assess its safety and tolerability, effects of food intake and to compare JNT-517 levels when taken as an oral suspension and tablet formulation.phenylketonuria

ACTRN12622001271796CTI Clinical Trial and Consulting Services Australia Pty Ltd.12

进行中（未招募）

1 期

Clinical trial to evaluate the safety and immune activation of DCVAC/PCa and ONCOS-102 in men with metastatic prostate cancer.advanced metastatic castration-resistant prostate cancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-004314-15-CZSOTIO a.s.15